MDR-103 is under clinical development by Medeor Therapeutics and currently in Phase I for Kidney Transplant Rejection. According to GlobalData, Phase I drugs for Kidney Transplant Rejection have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MDR-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MDR-103 overview

MDR-103 is under development for the treatment of kidney transplant rejection in delayed tolerance LDKT. The drug candidate comprises organ donor-derived CD34+ hematopoietic stem and progenitor cells and CD3+ T cells. MDR-101 is administered through intravenous route and is developed based on MDR-10X technology.

Medeor Therapeutics overview

Medeor Therapeutics is a biotechnology company that discover and develops cellular immunotherapies to immune and hematological diseases. The company is headquartered in South San Francisco, California, the US.

For a complete picture of MDR-103’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.